STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

	Item No	Recommendation	Response
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Indicated as Cohort in all appropriate sections
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Indicated in the section "abstract"
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Explanation provided in the "Introduction "section
Objectives	3	State specific objectives, including any prespecified hypotheses	These has been provided in ll. 33-34; 126-128
Methods			
Study design	4	Present key elements of study design early in the paper	Indicated in the sub section "study design and study population", ll. 131-180
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Indicated in the sub sections "study design and study population", ll. 131-180; "assessment of exposure, ll. 181-237; "outcome measures; ll. 239-248; "table 1: Overview of data collected in the CONCEPT cohort"
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Indicated in the sub sections "study design and study population", ll. 131-180; "assessment of exposure, ll. 181-237; "outcome measures; ll. 239-248;
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed	NA - No matching was done
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Indicated in the sub sections "assessment of exposure, ll. 181-237; "outcome measures; ll. 239-248
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Description of this item has been provided in table 1 - Overview of data collection
Bias	9	Describe any efforts to address potential sources of bias	Indicated in the sub sections

			"assessment of exposure, ll. 181-237; "outcome measures; ll. 239-248
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	An overview of data management has been provided in the sub section "Data management", ll. 250-257. Detailed description of the statistical analysis may be provided in the respective individual articles.
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	An overview of data management has been provided in the sub section "Data management", ll. 250-257. Detailed description of the statistical analysis may be provided in the respective individual articles.
		(*b*) Describe any methods used to examine subgroups and interactions	An overview of data management has been provided in the sub section "Data management", ll. 250-257. Detailed description of the statistical analysis may be provided in the respective individual articles.
		(*c*) Explain how missing data were addressed	Missing data for selected variables are described in Table 1 and Table 2.
		(*d*) If applicable, explain how loss to follow-up was addressed	Indicated in the sub sections "study design and study population", ll. 131-180.
		(*e*) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	This information has been provided in the flow chart, figure 1.
		(b) Give reasons for non-participation at each stage	This information has been provided in the flow chart, figure 1
		(c) Consider use of a flow diagram	Flow chart has been provided, figure 1

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Relevant characteristics of the participants and their distribution has been provided in Table 2
		(b) Indicate number of participants with missing data for each variable of interest	Information on missing values has been provided for each variable in Table 2 & Table 3
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	Table 2 and 3 provide a measure of important events at a baseline and follow-up
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 3 provides Confidence interval of the important outcome measures at baseline and on follow up
		(*b*) Report category boundaries when continuous variables were categorized	
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	NA. Cohort profile. However, summarized in "abstract".
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Indicated in the section "Strengths and limiations", ll. 319-338.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	NA. Cohort profile
Generalisability	21	Discuss the generalisability (external validity) of the study results	Indicated in the section "Strengths and limiations", ll. 319-338.
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Inidicated in the section "financial disclosure, ll. 359-361.

*Give information separately for exposed and unexposed groups.